CHDR proudly announces the establishment of a new research area: Translational Biomarkers headed by Dr. Matthijs Moerland
Drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot immediately be introduced in large clinical trials, but require rational exploration in tailored early phase clinical studies, with biomarkers that are fit-to-purpose. Furthermore, new investigational medicinal products are progressively of biotechnological nature (recombinant proteins, humanized antibodies, oligonucleotides). These recent evolutions in drug development require a more direct approach to monitor (intended and unintended) drug effects, which can be achieved by the selection of biomarkers that reflect early drug effects on cells or tissues. The availability of such proximal biomarkers allows a more efficient translation between different stages in drug development; from animals to humans, from in vitro experiments on human cells to clinical studies, and from healthy volunteers to the targeted patient population. These ‘translational biomarkers’ will play an increasingly important role in future drug development, not only in vascular medicine (vascular biology, inflammation, coagulation), but more and more also in therapeutic areas such as neurodegeneration and pain.
CHDR has anticipated on these evolutions, and proudly announces the establishment of a new research area entitled Translational Biomarkers. This research area, headed by long-term CHDR staff scientist Matthijs Moerland (PhD in vascular biology, clinical pharmacologist), will entail the selection, qualification and implementation of specific biomarkers in drug development. Translational Biomarkers will focus on cellular and chemical biomarkers reflecting proximal drug effects, and (in vitro and ex vivo) bioassays that guide drug development.